Loading...
XNAS
COO
Market cap10bUSD
Oct 08, Last price  
54.30USD
1D
-0.82%
1Q
-23.20%
Jan 2017
24.16%
Name

Cooper Companies Inc

Chart & performance

D1W1MN
XNAS:COO chart
P/E
28.25
P/S
2.59
EPS
1.92
Div yield, %
—
Shrs. gr., 5y
0.18%
Rev. gr., 5y
10.98%
Revenues
4.09b
+5.06%
858,960,000950,641,0001,063,176,0001,080,421,0001,158,517,0001,330,835,0001,445,136,0001,587,725,0001,717,776,0001,797,060,0001,966,814,0002,139,000,0002,532,800,0002,653,400,0002,430,900,0002,922,500,0003,308,400,0003,593,200,0003,895,400,0004,092,400,000
Net income
375m
-4.44%
66,234,000-11,192,00065,476,000100,548,000112,803,000175,430,000248,339,000296,151,000269,856,000203,523,000273,917,000372,900,000139,900,000466,700,000238,400,0002,944,700,000385,800,000294,200,000392,300,000374,900,000
CFO
796m
+12.24%
162,716,000133,984,00096,528,000223,128,000267,663,000336,281,000315,121,000415,925,000454,823,000390,970,000509,600,000593,600,000668,900,000713,200,000486,600,000738,600,000692,400,000607,500,000709,300,000796,100,000
Dividend
Jul 26, 20230.03 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

Related entities

Subsidiaries (16)
COOPERSURGICAL HOLDINGS LIMITED
COOPERVISION LIMITED
COOPERVISION MANUFACTURING LIMITED
CVI CONTACT LENS INDIA PRIVATE LIMITED
COOPERVISION (UK) HOLDINGS LIMITED
COOPERVISION CARIBBEAN CORP.
COOPERVISION CL HUNGARY KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG
COOPERVISION INTERNATIONAL HOLDING COMPANY, LP
COOPERVISION INTERNATIONAL LIMITED
COOPERVISION LENS CARE LIMITED
COOPERVISION MANUFACTURING COSTA RICA SOCIEDAD DE RESPONSABILIDAD LIMITADA
CooperVision Nordic Aktiebolag
ENSEYES ApS
ORIGIO A/S
ORIGIO INDIA PRIVATE LIMITED
ORIGIO LIMITED

Key people

Independent Chairman of the Board · since 2026
Robert Weiss
Director · since 2026
Albert White
President, Chief Executive Officer, Director · since 2018
Holly Sheffield
President - CooperSurgical, Inc · since 2020
Gerard Warner
President, CooperVision, Inc · since 2022
Daniel Mcbride
Chief Operating Officer, Executive Vice President · since 2022
Brian Andrews
Chief Financial Officer, Executive Vice President, Treasurer · since 2020
Agostino Ricupati
Senior Vice President - Finance and Tax, Chief Accounting Officer · since 2017
Vice President, General Counsel, Corporate Secretary · since 2022
Barbara Carbone
Independent Director · since 2025
Independent Director · since 2023
Independent Director · since 2022
Independent Director · since 2020
Maria Rivas
Independent Director · since 2021
Independent Director · since 2026
IPO date
Jan 21, 1983
Employees
15,000
Domiciled in
US
Incorporated in
US
Legal address
C/O THE PRENTICE-HALL CORPORATION SYSTEM, INC.
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
6101 Bollinger Canyon Road
San Ramon, CA 94583
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑102024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT